Estimating the Potential Medicare Savings from Comparative Effectiveness Research

通过比较有效性研究估计潜在的医疗保险节省

• 批准号: 8803229
• 负责人: ALAN Michael GARBER
• 金额: $ 47.23万
• 依托单位: HARVARD MEDICAL SCHOOL
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-04-01 至 2015-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8803229
• 关键词: Adoption; Advisory Committees; Affect; American; Area; Attention; Caring; Clinical; Cost Effectiveness Analysis; Cost Savings; Data; Data Analyses; Diagnostic; Disease; Economics; Effectiveness; Elderly; Expenditure; Frequencies; Future; Growth; Health; Health Expenditures; Health Insurance; Healthcare; Individual; Intervention; Investigation; Link; Malignant Neoplasms; Malignant neoplasm of prostate; Measures; Medical; Medicare; Medicare claim; Modeling; Outcome; Patients; Performance; Placebos; Policies; Policy Analysis; Population; Price; Process; Research; Savings; Subgroup; Techniques; Uncertainty; base; beneficiary; clinical efficacy; clinical practice; clinically relevant; cohort; comparative effectiveness; copayment; cost; cost effective; cost effectiveness; effectiveness research; improved; life time cost; payment; programs; research study

DESCRIPTION (provided by applicant): Comparative effectiveness research (CER) is intended to measure how alternative approaches to health care affect health outcomes. CER has the potential to reduce expenditures by limiting the use of both ineffective care and care that is no more effective than less costly alternatives. We propose to study the benefits that might accrue to Medicare from the application of CER to six high- priority medical areas. Our specific aims are to: 1. Identify areas of CER that have the greatest potential to improve the efficiency and appropriateness of care delivered to Medicare beneficiaries. 2. Estimate (long-term) incremental expenditures attributable to the use of competing strategies in these high-priority clinical areas. 3. Determine the expenditure implications for Medicare that would result from the adoption of clinical strategies supported by CER criteria, including cost-effectiveness, for each high-priority area, and to describe policy options (e.g. reference pricing, bundled payments, etc.) for implementing these findings for Medicare. Our analyses are principally based on complete Medicare claims files for Parts A and B from years 1991 to 2009 and Part D from 2006 to 2009. Data for the analysis of cancer management (e.g., localized prostate cancer), will include SEER-Medicare linked data. We will first select the medical areas for further research based upon a prioritization process considering, for each potential area of investigation, effects on total Medicare expenditures, potential for growth, and evidence of variability or uncertainty in clinical approaches. A distinguished expert Advisory Committee, representing health care, health insurance, and consumer perspectives, will provide close guidance for this component and several other aspects of the project. For each high-priority medical area selected, we will identify the relevant cohort from the Medicare claims files (or SEER-Medicare files) and assign individuals to management strategies based upon treatment or diagnostic interventions received. In addition to descriptive statistical analyses (frequency of the use of each strategy, rates of important outcomes, and total and related health expenditures), the project will include multivariate statistical analysis to investigate the relationship between strategy, outcome (including expenditures) and key variables. Where possible, we will use instrumental variable analysis and related techniques to control for bias in the selection of management strategies. Separate models will be estimated for important subgroups. We will estimate the potential consequences to Medicare of implementing our findings for each medical area by constructing a population model that shifts (with scenarios of varying degrees of adoption) patients to the strategy(ies) supported by our findings (least costly with equivalent outcomes or additional cost worth the incremental benefit based on cost-effectiveness analysis). Finally, we will investigate approaches that Medicare might use to implement these findings, including payment reform options such as bundled payments, reference pricing and value-based copayments.

描述（由申请人提供）：比较有效性研究（CER）旨在衡量替代医疗方法如何影响健康结果。CER有可能通过限制无效护理和不比成本较低的替代品更有效的护理的使用来减少支出。 我们建议研究CER在六个高优先级医疗领域的应用可能给医疗保险带来的好处。我们的具体目标是：1.确定CER中最有潜力提高向Medicare受益人提供护理的效率和适当性的领域。 2.估计（长期）增量支出归因于在这些高优先级的临床领域的竞争策略的使用。 3.确定采用CER标准支持的临床策略对医疗保险的支出影响，包括每个高优先领域的成本效益，并描述政策选项（例如参考定价，捆绑支付等）。将这些发现应用于医疗保险。 我们的分析主要基于1991年至2009年A部分和B部分以及2006年至2009年D部分的完整医疗保险索赔文件。用于分析癌症管理的数据（例如，局限性前列腺癌），将包括SEER-医疗保险相关数据。我们将首先选择医疗领域进行进一步的研究，根据优先顺序的过程中考虑，为每个潜在的调查领域，对医疗保险总支出的影响，增长的潜力，以及临床方法的可变性或不确定性的证据。一个杰出的专家咨询委员会，代表医疗保健，健康保险和消费者的观点，将提供密切的指导，这一组成部分和其他几个方面的项目。对于选定的每个高优先级医疗领域，我们将从Medicare索赔文件（或SEER-Medicare文件）中确定相关队列，并根据接受的治疗或诊断干预措施将个人分配到管理策略。除了描述性统计分析（每种策略的使用频率、重要结果的发生率以及总的和相关的卫生支出）之外，该项目还将包括多变量统计分析，以调查策略、结果（包括支出）和关键变量之间的关系。在可能的情况下，我们将使用工具变量分析和相关技术来控制管理策略选择中的偏差。对于重要亚组，将估计单独的模型。我们将通过构建一个人口模型，将患者转移（采用不同程度的场景）到我们的研究结果支持的策略（成本最低，具有相同的结果或额外的成本值得基于成本效益分析的增量效益），来估计在每个医疗领域实施我们的研究结果对医疗保险的潜在影响。最后，我们将调查医疗保险可能用于实施这些发现的方法，包括支付改革选项，如捆绑支付，参考定价和基于价值的共同支付。